Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation

Archives of Internal Medicine

Volumn 167, Issue 15, 2007, Pages 1648-1653

  Essebag, Vidal ^a   Reynolds, Matthew R ^b   Hadjis, Tom ^a   Lemery, Robert ^c   Olshansky, Brian ^d   Buxton, Alfred E ^e   Josephson, Mark E ^b   Zimetbaum, Peter ^b,f  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

^f HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; SOTALOL;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BODY MASS; BODY WEIGHT; BRADYCARDIA; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM PACING; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SICK SINUS SYNDROME; STATISTICAL ANALYSIS; TREATMENT INDICATION;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 34548044488     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.15.1648     Document Type: Article

References (42)

1. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352(18):1861-1872.
2. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342(13):913-920.
3. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42(1):20-29.
4. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med. 2003;163(7):777-785.
5. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791-798.
6. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100(19):2025-2034.
7. Essebag V, Hadjis T, Platt RW, Pilote L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol. 2003;41(2):249-254.
8. Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006;152(6):1097-1103.
9. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007;18(6):628-633.
10. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999;20:145-157.
11. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested casecontrol and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5(1):5.
12. Essebag V, Hadjis T, Platt RW, Abrahamowicz M, Pilote L. Effect of amiodarone dose on the risk of permanent pacemaker insertion. Pacing Clin Electrophysiol. 2004;27(11):1519-1525.
13. Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 1997;127(4):281-284.
14. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270(21):2590-2597.
15. Antonelli D, Atar S, Freedberg NA, Rosenfeld T. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. Isr Med Assoc J. 2005;7(3):163-165.
16. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sexbased differences and other issues. Am J Cardiol. 2003;91(6A):39D-44D.
17. Miller MA. Gender-based differences in the toxicity of pharmaceuticals - the Food and Drug Administration's perspective. Int J Toxicol. 2001;20(3):149-152.
18. Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A. Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam Clin Pharmacol. 2002;16(5):343-346.
19. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38(11):1003-1009.
20. Anderson GD. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase. J Gend Specif Med. 2002;5(1):25-33.
21. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.
22. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41(5):329-342.
23. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24(5):339-346.
24. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sexspecific differences after oral administration of verapamil. Clin Pharmacol Ther. 2000;68(3):286-292.
25. Vree TB, Dammers E, Valducci R. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. Int J Clin Pharmacol Ther. 2004;42(8):463-472.
26. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 1999;66(6):594-601.
27. Plomp TA, Hauer RN, Robles de Medina EO. Amiodarone and desethylamiodarone concentrations in plasma and tissues of surgically treated patients on longterm oral amiodarone treatment. In Vivo. 1990;4(2):97-100.
28. Falik R, Flores BT, Shaw L, Gibson GA, Josephson ME, Marchlinski FE. Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. Am J Med. 1987;82(6):1102-1108.
29. Brennan FJ, Brien JF, Armstrong PW. Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans. Can J Cardiol. 1991;7(3):117-124.
30. Pollak PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther. 2004;75(4):342-351.
31. El-Eraky H, Thomas SH. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. Br J Clin Pharmacol. 2003;56(2):198-204.
32. Bonnemeier H, Richardt G, Potratz J, et al. Circadian profile of cardiac autonomic nervous modulation in healthy subjects: differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol. 2003;14(8):791-799.
33. Burke JH, Goldberger JJ, Ehlert FA, Kruse JT, Parker MA, Kadish AH. Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect. Am J Med. 1996;100(5):537-543.
34. Liu S, Yuan S, Kongstad O, Olsson SB. Gender differences in the electrophysiological characteristics of atrioventricular conduction system and their clinical implications. Scand Cardiovasc J. 2001;35(5):313-317.
35. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35(1):13-29.
36. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
37. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-1840.
38. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-1696.
39. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789-1794.
40. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126(2):476-486.
41. Zimetbaum P, Josephson ME. Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Ann Intern Med. 2004;141(9):720-726.
42. Zimetbaum P. Is rate control or rhythm control preferable in patients with atrial fibrillation? an argument for maintenance of sinus rhythm in patients with atrial fibrillation. Circulation. 2005;111(23):3150-3157.